ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR

Key Points:

• ImmunityBio presented indirect treatment comparison analyses at AUA 2026 showing that nogapendekin alfa inbakicept-pmln (NAI) plus BCG doubled the complete response (CR) rate and more than doubled the median duration of CR compared to nadofaragene firadenovec-vncg in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
• NAI+BCG also reduced the risk of cystectomy by 60% compared to nadofaragene firadenovec-vncg and demonstrated numerically higher 12-month CR rates and significantly fewer treatment-related adverse events than TAR-200.
• The analyses used matching-adjusted indirect comparisons due to the lack of head-to-head trials, adjusting for key baseline variables, but results should be interpreted cautiously due to inherent limitations and potential residual confounding.
• ANKTIVA® (nogapendekin alfa inbakicept-pmln) is a first-in-class IL-15 receptor agonist designed to activate NK and CD8+ T cells to overcome tumor resistance and generate durable immune memory, offering a promising bladder-sparing option for patients with BCG-unresponsive NMIBC.
• ImmunityBio emphasized ongoing efforts to address the U.S. shortage of conventional BCG by developing recombinant BCG and the Tokyo strain BCG, with availability limited to an FDA Expanded Access Program, while highlighting the importance of shared decision-making in treatment selection.